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Abstract: There is a lack of consistent guidelines and consensus for the diagnosis of 
laryngopharyngeal reﬂ  ux (LPR). A therapeutic trial with a proton pump inhibitor (PPI) has 
been suggested to identify patients with LPR. This review focuses on the current difﬁ  culties in 
diagnosing the disease and examines the evidence for the effectiveness of PPI therapy in sus-
pected reﬂ  ux-related laryngeal symptoms. Additionally, mode of action, safety, and tolerability 
of PPIs are described. A total of 7 placebo-controlled trials were identiﬁ  ed and included in the 
review. All studies evaluated the effect of a PPI on symptoms and objective laryngoscopic ﬁ  nd-
ings in suspected LPR. Data from these trials show that PPI therapy is no more effective than 
placebo in producing symptom relief in patients suspected of LPR. Symptoms, laryngoscopic 
ﬁ  ndings, or abnormal ﬁ  ndings on pH monitoring will not predict response to PPI therapy. High 
placebo response levels suggest a much more complex and multifactorial pathophysiology of 
LPR than simple acid reﬂ  ux. Further studies are needed to characterize subgroups of patients 
with reﬂ  ux-associated laryngeal symptoms that might beneﬁ  t from treatment with PPI. Future 
studies should use validated patient reported outcome measures with endpoints that represent 
a predeﬁ  ned clinically meaningful change in symptom scores.
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Introduction
A causal association between reﬂ  ux of acidic gastric contents and symptoms and signs 
of laryngopharyngitis is plausible given the close anatomical relationship between the 
oesophagus and the hypopharynx and larynx. Reﬂ  uxed material from the stomach, 
including acid and pepsin, may lead to direct chemical injuries and inﬂ  ammation of the 
mucosa of the laryngopharyngeal structures, or may indirectly stimulate vagal afferents 
in the oesophagus. This is often referred to as reﬂ  ux laryngitis or laryngopharyngeal 
reﬂ  ux (LPR). It is estimated that 4%–10% of patients who consult ENT specialists do 
so because of complaints related to gastro-oesophageal reﬂ  ux.
An association between gastro-oesophageal reﬂ  ux symptoms and laryngeal 
symptoms such as hoarseness, cough, globus sensation, throat clearing, laryngitis and 
pharyngitis is supported by observations of frequent occurrence of these symptoms in 
patients with gastro-oesophageal reﬂ  ux disease (GERD). In an Italian study, 74.4% 
of GERD patients had at least one extra-oesophageal symptom and throat symptoms 
were reported by 19.9%–38.7% of the patients (Dore et al 2007).
There is a lack of consistent guidelines and consensus for the diagnosis of LPR 
(Ahmed et al 2006). The most common symptoms used to diagnose LPR include 
globus, throat clearing, cough, hoarseness, sore or burning throat, dysphagia, and 
dysphonia (Vaezi et al 2003). However, these symptoms are not speciﬁ  c for reﬂ  ux 
induced damage and can also be associated with smoking, voice abuse, allergies, and 
viral infections. Prior reports have shown that less than 30% of patients with extra-
oesophageal manifestations of reﬂ  ux have endoscopic evidence of oesophagitis (Vaezi 
et al 2003; Ahmed et al 2006).Therapeutics and Clinical Risk Management 2008:4(1) 226
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The most useful laryngeal signs for LPR are reported to 
be erythema, oedema, presence of a posterior commisure 
bar and cobble stoning (Ahmed, Khandwala, Abelson et al 
2006). Recent data have documented a high intra- and 
interobserver variability of laryngeal examination, making 
the laryngoscopic diagnosis of LPR highly subjective. This 
increases the likelihood that many patients diagnosed with 
LPR based on objective ﬁ  ndings may actually not have 
the disease (Branski et al 2002). Furthermore, generally 
accepted laryngoscopic signs of LPR can be found in up to 
70% of healthy, normal volunteers (Hicks et al 2002). Thus, 
laryngoscopic ﬁ  ndings are neither speciﬁ  c nor sensitive in 
the diagnosis of LPR.
Even though dual-channel pharyngo-oesophageal 24-h 
pH monitoring is considered the diagnostic gold standard 
for LPR by some (Noordzij et al 2001; Habermann et al 
2002) the role of pH testing in the diagnosis of LPR remains 
controversial (Vaezi et al 2003). Proximal oesophageal and 
hypopharyngeal pH testing are not widely available and are 
considered less useful by both community and academic 
gastroenterologists (Ahmed et al 2006), and there is a lack of 
consensus on how much reﬂ  ux in the hypopharynx is normal. 
Most studies show that hypopharyngeal pH-monitoring is not 
a predictor of response to acid inhibitory therapy as response 
to therapy is no more likely in individuals with abnormal 
hypopharyngeal acid reﬂ  ux compared to individuals with no 
acid reﬂ  ux (El-Serag et al 2001; Noordzij et al 2001; Vaezi 
et al 2003; Williams et al 2004; Vaezi et al 2006; Wo et al 
2006). Finally it should be taken into account that oesopha-
geal pH-monitoring is not even a perfect gold standard test for 
GERD. Contrary to this view, Haberman et al (2002) found 
that patients with a positive pH monitoring had signiﬁ  cant 
improvement in all symptoms, whereas in patients with a 
negative pH monitoring no statistically signiﬁ  cant change 
was seen after open label pantoprazole. From this result, the 
authors argued that empirical acid inhibitory therapy serves 
to select patients with reﬂ  ux-related problems from those 
without detectable reﬂ  ux. This conclusion may be seriously 
ﬂ  awed, though. The decrease in symptom scores was the 
same for both groups and the apparent difference in statistical 
outcomes was related to a small number of patients (n = 7) 
in the negative pH monitoring group.
A therapeutic trial with a proton pump inhibitor (PPI) has 
been suggested as a useful and cost-effective way of identify-
ing patients with true reﬂ  ux-related laryngopharyngeal symp-
toms (Ahmed et al 2006). A number of uncontrolled patient 
series have suggested that a positive response to empiric PPI 
therapy for 2–3 months will reliably establish a diagnosis 
of LPR. This review examines the evidence for the current 
recommendations of PPI therapy of suspected LPR.
Patient reported outcomes 
in laryngopharyngeal reﬂ  ux
Apparently, 25% of LPR patients experience spontaneous 
symptom resolution and 50% have a chronic course with 
intermittent exacerbations and remissions (Ford 2005), stress-
ing the importance of double-blind, controlled evaluations 
using validated symptom response instruments.
In contrast to GERD, in which heartburn is the primary 
symptom, there is no predominant symptom for LPR. 
Accordingly, most studies have evaluated a number of 
symptoms or focused on changes in a single predominant 
throat symptom identiﬁ  ed by the patient.
A number of composite symptom scores have been 
introduced but they have not been adequately validated. Vari-
ous modiﬁ  cations of the Laryngeal Symptom Score (LSS) 
have been used in some studies (Williams et al 2004; Wo 
et al 2006; Qua et al 2007). The frequency and severity of a 
number (usually up to 6) of LPR symptoms are assessed over 
the preceding week to give a cumulative score.
The Reﬂ  ux Symptom Index asks patients to grade 8 dif-
ferent throat symptoms and heartburn on a 6-graded scale 
(Belafsky et al 2002). This questionnaire has not been vali-
dated as a tool to identify patients with reﬂ  ux induced laryn-
gopharyngeal symptoms. A reﬂ  ux symptom questionnaire 
has been modiﬁ  ed to include laryngopharyngeal questions 
and was used in the study by Steward et al (2004).
Presence of moderate-to-severe GERD disqualified 
patients in some studies (Havas et al 1999; Vaezi et al 
2006). Excluding patients with frequent heartburn or severe 
esophagitis might be problematic as the study population 
may not reﬂ  ect daily clinical practice. On the other hand, 
there is concern over the ethical aspects of allocating patients 
with moderate to severe GERD to a placebo treatment arm. 
Furthermore, a high withdrawal rate might jeopardize the 
interpretation of the trial.
Health-related quality of life
The laryngopharyngeal reﬂ  ux-health-related quality of life 
(LPR-HRQL) questionnaire is a 43-item instrument which 
assesses functional consequences of symptoms related to 
reﬂ  ux laryngitis on the patients’ daily life over the previous 
4 weeks. The reliability, validity and responsiveness of the 
instrument has been tested (Carrau et al 2004; Carrau et al 
2005). The questionnaire was found responsive to interven-
tion 4 and 6 months into therapy. Unfortunately, earlier Therapeutics and Clinical Risk Management 2008:4(1) 227
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effects of therapy were not tested. The instrument has not 
been used in controlled PPI trials.
Other outcome measures 
in laryngopharyngeal reﬂ  ux
Laryngoscopic ﬁ  ndings
All controlled PPI trials included patients with laryngoscopic 
ﬁ  ndings compatible with LPR, ﬁ  ndings that were evaluated 
with a new laryngoscopic examination at the end of therapy.
Most studies used a composite score based on gradings of 
laryngoscopic signs such as oedema, erythema, granuloma, 
ulcer, and amount of mucus as an outcome measure. Clini-
cally relevant changes in these scores were not determined 
beforehand.
The precise correlation between laryngitis and symp-
toms remains unclear. Endoscopic signs of laryngitis may 
improve despite no discernible changes in symptom status 
(Williams et al 2004). On the other hand, a study has shown 
that the physical ﬁ  ndings of LPR resolve more slowly than 
the symptoms (Belafsky 2001).
pH monitoring
Most PPI studies included a dual-channel pH-monitoring at 
entry but only one study repeated the examination at the end 
of therapy (Wo et al 2006).
Other outcome measures
Other outcome measures have included changes in lifestyle 
factors related to reﬂ  ux, changes in the SF-36 generic qual-
ity of life questionnaire and changes in voice quality as 
assessed by a computerized voice analysis (Steward et al 
2004; Williams et al 2004).
Mode of action and efﬁ  cacy 
of proton pump inhibitors
PPIs are substituted benzimidazoles. After oral administra-
tion they are absorbed in the small intestine as prodrugs and 
accumulate in the acidic environment of the canaliculi of the 
parietal cells where they are protonated and converted to an 
active and relatively stable sulfenamide form. This binds 
irreversibly to speciﬁ  c subunits on the outside surface of the 
luminal H+/K+-ATPase. As the ﬁ  nal step in acid secretion 
involves activation of this enzyme, PPI therapy will reduce 
gastric acidity by inhibiting both basal and activated acid 
secretion (Horn 2000).
Five PPIs are currently widely available: esomeprazole, 
lansoprazole, omeprazole, pantoprazole, and rabeprazole. 
The last four compounds are racemic isomer mixtures, 
whereas esomeprazole includes only the S isomer of ome-
prazole. There are subtle structural differences between the 
various PPIs that may affect aspects of their antisecretory 
activity and clinical utility (Bytzer 2006).
Once-daily dosing in the morning is more effective than 
dosing in the evening for all PPIs with respect to the suppres-
sion of intragastric acidity and daytime gastric acid secretion 
in particular. This may result from a better bioavailability 
being achieved with the morning dose. When higher doses are 
needed, these drugs should be given twice daily to achieve the 
optimal suppression of intragastric acidity. On twice-a-day 
dosing, inhibition of acid secretory capacity improves to 80% 
of maximally stimulated output (Sachs et al 2000).
PPIs are the drugs of choice for the treatment of GERD. 
They are highly effective in healing erosive GERD and in 
long-term resolution of acid-related symptoms (Jones and 
Bytzer 2001). Clinical data suggest that the optimal daily 
dose of PPIs for acute treatment of reﬂ  ux-related symptoms 
and mucosal damage is about 30–40 mg. In less severe cases 
and in maintenance therapy doses of 10–20 mg daily may be 
sufﬁ  cient (Kromer et al 1999). Standard-dose PPIs heal ero-
sive esophagitis in more than 90% of patients after 8 weeks 
of treatment and achieve high symptom response rates com-
pared with H2-receptor antagonists (Chiba et al 1997).
All PPIs are very safe drugs with an adverse event proﬁ  le 
not different to placebo (Reilly 1999). The extensive clini-
cal experience with PPIs has shown these agents to be well 
tolerated with a low risk of clinically relevant drug-drug 
interactions (Gerson and Triadaﬁ  lopoulos 2001).
PPIs are considered the mainstay of therapy in LPR 
although there is controversy regarding their efﬁ  cacy.
Results from open-label trials
Recommendations of treatment with PPIs in suspected LPR are 
based on the results of a number of open label studies (Kamel 
et al 1994; Hanson 1995; Jaspersen et al 1996; Habermann et al 
1999; Shaw and Searl 1997; Wo et al 1997; Ulualp et al 2001; 
Delgaudio and Waring 2003; Park et al 2005; Siupsinskiene 
et al 2007). These are all uncontrolled studies investigating the 
effect of a PPI at varying doses on symptoms and laryngeal 
ﬁ  ndings with treatment lasting from 6 to 24 weeks. In all stud-
ies there was a statistically signiﬁ  cant improvement of both 
laryngeal symptoms and laryngoscopic ﬁ  ndings at the end 
of therapy. The clinically signiﬁ  cant measure for symptom 
improvement was deﬁ  ned in only 5 (Wo; Delgaudio; Park; 
Hanson; Jaspersen) of the 8 trials summarized in Table 1. 
The remaining 3 trials (Kamel; Habermann; Shaw) reported Therapeutics and Clinical Risk Management 2008:4(1) 228
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changes in composite symptom scores after therapy as proof 
of therapeutic effect. The clinical relevance of such overall 
change might be questioned.
Symptoms were rated by a number of different non-
validated questionnaires with remarkably high and variable 
response rates ranging from 60% to 100%.
Results from placebo-controlled 
trials
Six double-blinded placebo-controlled parallel studies and 
one placebo-controlled crossover trial were identiﬁ  ed. All 
studies evaluated the effect of a PPI on symptoms and objec-
tive laryngoscopic ﬁ  ndings. Ambulatory pH monitoring was 
performed in all studies, however abnormal results were 
used as inclusion criteria in only three studies (Noordzij et al 
2001; Eherer et al 2003; Wo et al 2006). In only one study 
oesophageal symptoms of gastroesophageal reﬂ  ux disease 
(heartburn) were speciﬁ  cally deﬁ  ned as an exclusion criteria 
(Vaezi et al 2006). In all other studies these symptoms were 
not required to enter nor did they exclude patients from 
participation.
The ﬁ  rst published double-blinded placebo-controlled 
trial was a study by Havas et al (1999). Twenty patients 
with symptoms and laryngoscopic signs of LPR presenting 
to one single otolaryngologist were randomized to treat-
ment with lansoprazole 30 mg bid or placebo for 12 weeks. 
Patients with pre-existing anti-secretory therapy or severe 
reﬂ  ux oesophagitis at endoscopy were excluded. Patients 
were investigated with upper GI endoscopy, oesophageal 
manometry, and dual pH probe monitoring. The presence of 
typical reﬂ  ux symptoms were registered at study entry. Sever-
ity and frequency of throat symptoms and laryngoscopic 
ﬁ  ndings were evaluated at baseline, and after 6 and 12 weeks. 
Data from 15 patients were available for analysis.
Symptoms and laryngoscopic ﬁ  ndings improved in both 
groups with no signiﬁ  cant differences between lansoprazole 
and placebo. Even when data were analyzed based on the 
results of the pH monitoring no differences between placebo 
and active drug could be discerned.
In a study by Wo et al (2006) 39 patients with symp-
toms of LPR and a positive triple-sensor pH test were 
randomized after a 2-week run-in to double-blind treatment 
Table 1 Summary of open-label trials assessing effects of PPI therapy on symptoms of LPR 
Study  No of   Inclusion criteria  Medication  Duration of  Outcome measure
 patients      treatment 
       (wk) 
Kamel (1994)  16  Persisting LPR symptoms  Omeprazole 40 mg od,  6–24  Unspeciﬁ  ed change from
    and signs despite prior  increased to 40 mg bid     baseline in mean composite
    H2RA treatment  in 6 pt.s with ongoing     symptom score
     symptoms
Hanson (1995)  41  LPR symptoms and signs  Omeprazole 40 mg od  4  Resolution of symptoms
    unresponsive to nocturnal
   anti-reﬂ  ux precautions
Jaspersen (1996)  21  LPR symptoms and signs  Omeprazole 40 mg od  4  Resolution of symptoms
    and oesophagitis at upper
   GI  endoscopy
Shaw (1997)  96  LPR symptoms  Omeprazole 20 mg od  12  Unspeciﬁ  ed improvement in
         symptoms
Wo (1997)  21  LPR symptoms and signs  Omeprazole 40 mg od  8  Resolution of symptoms or
          patient reported satisfactory
          effect of treatment
Habermann (1999)  29  Voice disorders and  Pantoprazole 40 mg od  6  Unspeciﬁ  ed change from
    symptoms of LPR      baseline in mean composite
         symptom  score
Delgaudio (2003)  30  LPR symptoms  Esomeprazole 40 mg od  8  Reduction of at least 50% in
          symptom score and remaining
          symptoms no morte than mild
         in  severity
Park (2005)  85  LPR symptoms and signs  Lansoprazole 30 mg bid (n = 30),  16  Reduction of at least 50% in
      omprazole 20 mg bid (n = 30),    primary symptom score
      esomprazole 40 mg od (n = 25)   
Abbreviations: LPR, laryngopharyngeal reﬂ  ux; PPI, proton pump inhibitor.Therapeutics and Clinical Risk Management 2008:4(1) 229
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with pantoprazole 20 once daily or placebo for 12 weeks 
followed by a 4-week follow-up of treatment. Laryngeal 
ﬁ  ndings were scored using the Reﬂ  ux Finding Score prior 
to enrolment and after treatment. The triple-sensor pH test 
was repeated in week 12 on treatment to conﬁ  rm acid sup-
pression. Patients scored the severity of both laryngeal and 
oesophageal symptoms weekly and assessed if they had 
adequate relief of symptoms.
Symptoms improved during the treatment period in both 
study groups with no signiﬁ  cant difference. Adequate relief 
by the end of the treatment period was reported by 40% in 
the pantoprazole group and 42% in the placebo group. There 
was no signiﬁ  cant improvement in the Reﬂ  ux Finding Score 
before and after treatment in subjects randomized to panto-
prazole as well as no differences between pre- and post treat-
ment hypopharyngeal reﬂ  ux episodes in either group. There 
was no correlation between laryngeal ﬁ  ndings or suppression 
of acid reﬂ  ux and symptom improvement.
In a double-blinded placebo-controlled study by Noordzij 
et al (2001), patients with symptoms of LPR were investi-
gated with a 24-hour dual-channel pH probe study. A total of 
30 patients with a positive pH study were randomly assigned 
to treatment with omeprazole 40 mg or placebo twice a day 
for 2 months. Laryngeal symptoms and laryngoscopic signs 
of LPR were recorded at study entry and after 1 and 2 months 
of treatment. Symptom scores were assessed by multiplying 
the number of days with symptoms over the past 2 weeks 
with the severity of each symptom rated on a visual analog 
scale from none to most severe.
Symptom scores improved over time for both treatment 
groups with no signiﬁ  cant differences. By performing 
secondary analysis the authors were able to demonstrate 
a statistically signiﬁ  cant improvement for 2 laryngeal 
symptoms (mild hoarseness and throat clearing) in the 
omeprazole group compared with the placebo group, but 
not for other LPR symptoms, nor for heartburn. There was 
no signiﬁ  cant change in endoscopic laryngeal ﬁ  ndings in 
either group.
In a placebo-controlled crossover trial (Eherer et al 2003) 
21 patients with symptoms suggestive of laryngitis and 
abnormal oesophageal or pharyngeal pH-study were rand-
omized to treatment with pantoprazole 40 mg bid or placebo 
for 3 months, each separated by a 2-week washout period. 
Patients scored intensity and frequency of both laryngeal 
and oesophageal symptoms and were scored for laryngeal 
changes at baseline and at the end of each 3 months treatment 
period. By the end of the 2-week wash-out period, 14 of the 
21 patients underwent a second pH-study.
There were no signiﬁ  cant changes in symptom scores 
after the ﬁ  rst treatment period within or between the groups 
for either oesophageal or laryngeal symptoms. After reversal 
of treatments there was no signiﬁ  cant change in symptom 
scores in any group. A signiﬁ  cant decrease in laryngeal scores 
after 3 months of treatment was seen in both the pantoprazole 
and the placebo group. This decrease was maintained in both 
groups after switch of treatment.
In another double-blind, randomized placebo-controlled 
trial (Steward et al 2004) 42 patients with laryngeal symp-
toms and objective ﬁ  ndings suggestive of LPR underwent 
a distal and proximal oesophageal 24-h pH monitoring. 
Questionnaires with assessment of frequency and severity 
of typical reﬂ  ux symptoms and laryngeal symptoms as well 
as SF-36 were ﬁ  lled out prior to randomization to 2 months 
treatment with rabeprazole 20 mg bid or placebo and by the 
end of the treatment period. In addition, patients in both 
groups were instructed on relevant lifestyle modiﬁ  cations. 
Outcome measures included change in total symptom scores 
and proportion of subjects with signiﬁ  cant global improve-
ment.
Both rabeprazole- and placebo-treated patients demon-
strated signiﬁ  cant improvement in total symptom scores 
with no statistically signiﬁ  cant differences between the two 
groups.
The largest study to date is a multicenter, double-blind, 
placebo-controlled study by Vaezi et al (2006). A total of 146 
patients with laryngeal symptoms and laryngoscopic signs 
consistent with laryngopharyngeal reﬂ  ux were randomized 
in a 2:1 ratio to esomeprazole 40 mg or placebo twice a day 
for 16 weeks. Patients with moderate to severe heartburn in 
the preceding 3 weeks were excluded. Before randomization 
patients underwent a 7- to 14-day screening period with daily 
registration of 5 different laryngeal symptoms. By the end of 
the screening period patients identiﬁ  ed their single most both-
ersome symptom. To be eligible for randomization patients 
were required to report at least moderately severe symptoms 
for a minimum of 3 days. Before receiving study medication 
patients were offered a pharyngo-oesophageal pH monitoring 
with 3 probes proximally and distally in the oesophagus and 
in the hypopharynx. Additionally patient quality of life was 
assessed using the laryngopharyngeal reﬂ  ux-health-related 
quality of life (LPR-HRQL) questionnaire at baseline and at 
the ﬁ  nal visit. Patients reported daily symptoms on a diary 
card throughout the treatment period. The primary outcome 
measure was the percentage of patients who had resolution of 
the most bothersome symptom at the ﬁ  nal visit. Resolution of 
symptoms was deﬁ  ned as a severity score of 0 (none) during Therapeutics and Clinical Risk Management 2008:4(1) 231
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the last 7 days of the study, allowing symptoms of minimal 
severity for up to 3 days.
Resolution of the primary symptom was obtained in 
14.7% and 16.0% in the esomeprazole and placebo groups, 
respectively with no statistically significant difference. 
For secondary outcome measures, such as improvement in 
laryngeal signs, relief of primary symptom and improve-
ment in LPR-HRQOL, there was no difference between the 
treatment groups.
The only double-blind, randomized placebo-controlled 
study that claims a statistically signiﬁ  cant effect of a PPI 
on laryngeal symptoms was performed by El-Serag and co-
workers (El-Serag et al 2001). Of 27 patients diagnosed with 
idiopathic chronic laryngitis, who were referred to endoscopy 
and a 24-hour pH study from one single otolaryngologist, a 
total of 22 patients were randomized to 3 months treatment 
with lansoprazole 30 mg bid or placebo. Oesophageal and 
laryngeal symptoms were scored at entry, after 6 weeks of 
treatment and at the end of the study. Additionally, laryngeal 
ﬁ  ndings were evaluated prior to enrolment and after treatment. 
High-grade laryngoscopic ﬁ  ndings suggestive of reﬂ  ux, such 
as contact ulcers and granuloma, were found in 5 and 1 of the 
12 patients in the lansoprazole group and in 1 and 0 of the 
10 patients in the placebo group, respectively. Two patients 
dropped out after randomization leaving 11 and 9 patients in 
the lansoprazole and placebo groups, respectively.
The primary outcome measure was complete symptom 
resolution for laryngeal symptoms, which was found in 6/12 
patients (50%) in the lansoprazole group. According to the 
authors, this was signiﬁ  cantly higher than the response rate 
of 10% (1/10) in the placebo group. However, a two-sided 
Fisher’s exact test reveals a non-significant p-value of 
0.069 for this difference. Restricting the analysis to the 20 
per protocol patients does not improve the p-value, which 
remains insigniﬁ  cant at p = 0.074 when applying a cor-
rect non-parametric test, which adjusts for small cell size. 
Baseline oesophageal and laryngeal examinations, signs and 
symptoms did not predict response to therapy.
Results from meta-analyses
Qadeer et al (2006) performed a meta-analysis of eight 
randomized controlled trials, including a small study from 
2001 which remains published only in abstract form (Lan-
gevin and Hanh 2001). Study results were pooled and ana-
lyzed in order to estimate the overall efﬁ  cacy of PPI therapy 
in suspected LPR. The proportion of patients in each study 
who reported  50% reduction in laryngeal symptoms com-
pared with baseline was abstracted. Data from the studies 
were also analyzed to identify potential factors that could 
be associated with this primary outcome.
Pooled absolute rates of response, deﬁ  ned as  50% 
reduction in laryngeal symptoms, in the PPI and placebo 
groups were 50% (98/195) and 41% (61/149), respectively, 
which represent a non-signiﬁ  cant symptom reduction with 
PPI compared with placebo. No signiﬁ  cant clinical predictors 
of response to therapy were identiﬁ  ed. A funnel plot analysis 
showed evidence of publication bias with two studies outside 
the funnel; both these studies (El-Serag et al 2001; Langevin 
and Hanh 2001) claimed a signiﬁ  cant PPI beneﬁ  t.
Another recent meta-analysis by Gatta et al (2007) 
analyzed 5 studies with a total of 247 patients, including 
a trial on chronic cough patients with no data on laryngeal 
examinations (Ours et al 1999). Four of these studies were 
also included in the meta-analysis by Qadeer. The pooled 
relative risk (RR) of reporting symptomatic improvement 
or resolution of symptoms and the proportion of patients 
responding to active treatment or placebo was calculated as 
well as the number needed to treat (NNT).
With a pooled RR of 1.18, a non-signiﬁ  cant difference 
in response rate of 3.6% between the treatment group (25%) 
and the placebo group (21.4%) and a NNT of 53, the authors 
concluded that treatment with PPIs is no more effective 
than placebo in resolving or improving laryngo-pharyngeal 
symptoms presumed to be due to GERD. Funnel plot analysis 
showed an asymmetry suggesting the potential for publica-
tion bias or small study effects.
Conclusions
Data from controlled treatment trials convincingly show that 
PPI therapy is no more effective than placebo in producing 
symptom relief in patients suspected of laryngo-pharyngeal 
reﬂ  ux disease. Furthermore, neither symptoms, nor laryn-
goscopic ﬁ  ndings or abnormal ﬁ  ndings on pH monitoring 
will predict response to PPI therapy. A reliable diagnostic 
test for LPR or one that might predict response to a PPI 
does not exist.
Surprisingly, empiric PPI therapy for 2–3 months is still 
recommended in clinical reviews and guidelines as the most 
cost-effective and useful approach to the initial diagnosis of 
LPR (Delgaudio and Waring 2003; Ford 2005; Dore et al 
2007). Because of the high placebo response rates seen 
in the clinical trials a positive outcome of therapy in daily 
clinical practice should only cautiously be taken as proof of 
an established association between acid reﬂ  ux and laryngeal 
symptoms. Therefore, PPI therapy should always be followed 
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is actually due to acid suppression or represents a placebo 
response or spontaneous resolution of symptoms.
The relative inefﬁ  cacy of PPI treatment also challenges 
the current diagnosis pattern of LPR based on unspeciﬁ  c 
symptoms and ﬁ  ndings and a controversial role of pH-
monitoring. This may lead to overdiagnosis of the disease 
with disappointing outcome of acid suppressive therapy as a 
result. Especially laryngoscopic ﬁ  ndings seem to be difﬁ  cult 
to interpret with high inter- and intra-observer variability 
leading to uncertain correlation between symptoms, endo-
scopic signs and response to therapy.
The results from the high quality study by Vaezi et al 
(Vaezi, Richter, Stasney et al 2006) with very low response 
rates and without signiﬁ  cant difference in response between 
PPI therapy and placebo makes it reasonable to conclude that 
patients without typical symptoms of GERD (heartburn) will 
not beneﬁ  t from PPI therapy. Unlike with GERD, response 
to PPI therapy in patients with LPR has been highly variable. 
Some have argued that this is in part because LPR patients 
require higher doses and prolonged therapy compared to 
GERD patients. Several experts have recommended that 
the empiric therapy has to be aggressive with a period of 
treatment of at least 2–3 months. However, the results from 
placebo-controlled double-blind trials and from the meta-
analyses suggest that lack of response to empiric PPI should 
not lead to an escalation of dose or treatment length, but 
rather to a revised diagnosis.
The placebo response rates in most clinical trials were 
remarkably higher than the placebo response rates gener-
ally seen in randomized trials estimating the symptomatic 
effects of PPI therapy in patients with GERD, and were at 
a level comparable to that seen in functional GI disorders. 
This indicates that the causes of LPR are much more com-
plex and multifactorial than can be explained by the simple 
chemical injury associated with reﬂ  uxed stomach contents. 
This calls for further studies to help characterize subgroups 
of patients with reﬂ  ux-associated laryngeal symptoms that 
might beneﬁ  t from treatment with a PPI. Studies that utilize 
validated patient reported outcome measures with endpoints 
that represent a predeﬁ  ned clinically meaningful change in 
symptom scores are needed.
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